Bringing the original, cutting-edge, liposomal technology to superior pharmaceuticals and nutraceuticals

A group of scientists led by William A, Heriot—the primary inventor of three U.S. and multiple worldwide patents for liposome manufacture—was instrumental in the success of Phase 1 and Phase 2 Clinical Trials for Diclofenac, a liposome encapsulated drug for the treatment of osteoarthritis.

With degrees in Biochemistry, Organic Chemistry and Biophysics from the University of California, Berkeley, Heriot’s early career encompassed several important contributions to the chemical and pharmaceutical fields, including specialized products for control of the Mediterranean fruit fly for the U.S. Department of Agriculture, and for chemical light products used by the U.S. Department of Defense in both Gulf Wars. With the development of the new liposomal technology, Heriot founded Lippomix, which soon became the trusted source for pharmaceuticals and nutraceuticals.

The demand for efficient, effective natural supplements quickly escalated. In order to maintain our precise formulation and exceptional production quality, Lippomix was urged to manufacture these formulations in our state-of-the-art pharmaceutical facility. With fully equipped laboratories, mass production capabilities, and an extensive research library, Lippomix continually develops pharmaceutical and nutraceutical products that ensure superior delivery and absorption of this groundbreaking technology.

Scientific Advisory Board:

• Frederic (Rick) Troy
• Sandra Reynoso Rogers, PhD, MBA
• Brian Rogers, PhD, MBA, BS, Diplomate, American Board of Toxicology
• Jon Fukuto, PhD
• Vaughn Smider, MD, PhD

Frederic (Rick) Troy

• Professor of Biochemistry & Molecular Medicine at UC School of Medicine, Davis, CA;
  
• Member of UCD Comprehensive Cancer Center, Davis, CA;
  
• American Cancer Postdoctoral Fellow at Johns Hopkins University School of Medicine, Baltimore, MD, June 1966 – August 1988.
• Back To Top
  

• PhD in Immunology from UC Davis, Davis, CA MBA from UC Davis
• Founder and COO of Sialogen Therapeutics, a company focused on the development of novel oncology treatments to halt the growth of metastatic cancer cells;
• Managing Director of LabVet Bio Pacific (LVBP), a leading South American provider of veterinary diagnostic pathology services;
• Previous scientific and business advisor to numerous biotechnology firms following experience at biotechnology/pharmaceutical companies including Genentech, Syntex, and Arris Pharmaceuticals;
• Native of Peru, specialist in identifying and developing scientific business opportunities in developing countries.

Back To Top

Brian Rogers, PhD, MBA, BS, Diplomate, American Board of Toxicology
PhD in Toxicology from University of North Carolina, Chapel Hill, NC MBA from UC Davis, Davis, CA BS in Environmental Toxicology from UC Davis

• Participant in over 100 Investigation New Drug Applications (INDs) and over a dozen New Drug Applications (NDAs);
• Founder of Pacific BioDevelopment LLC (PBD), which serves biotechnology and pharmaceutical firms in a number of technical areas and with regulatory issues;
• Previous scientist at Genentech;
• Advisor to companies on various product safety issues (as Board Certified Toxicologist);
• Former adjunct professor at UC Davis, Graduate School of Management;
• Board member for scientific and/or business advisory boards.
  Back To Top

Jon Fukuto, PhD

• PhD in Chemistry from UC Berkeley, Berkely, CA
• Postdoctoral and Professor in Pharmacology from UCLA
• Currently Professor in Sonoma State University and Scientific Advisory Board of Cardioxyl Pharmaceuticals.

Back To Top

Vaughn Smider, MD, PhD MD from Stanford University, Stanford, CA

• PhD from Stanford University
• Assistant Professor of Molecular Biology, Department of Cell and Molecular Biology California Campus;
• Current faculty of The Scripps Research Institute.